Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNA, U6 small nuclear 264, pseudogene (RNU6-264P)** is a human genomic sequence classified as a pseudogene of the U6 small nuclear RNA (snRNA) gene family[2][5]. U6 snRNAs are essential non-coding RNAs involved in pre-mRNA splicing as components of the spliceosome complex[3]. However, like other U6 pseudogenes, RNU6-264P does not have known expression, protein product, or biological function[2][4][5]. Pseudogenes such as RNU6-264P typically arise from gene duplication or retrotransposition events and accumulate mutations that prevent them from producing functional RNA or protein[5]. Therefore, RNU6-264P is not regarded as a therapeutic target, is not involved in any identifiable cellular pathways or diseases, has no known drug interactions, and carries no clinical or safety significance.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 264, pseudogene (RNU6-264P).